FutuRx Portfolio

  • A2i Therapeutics

    A2i Therapeutics Ltd. is a joint venture of FutuRx and Atomwise, designed to utilize Atomwise’s AI platform, AtomNet® technology, to target ADAR1, a key protein involved in controlling the innate immune response, neurological disorders, metabolic diseases and potentially a key target for immuno-oncology and neurological homeostasis. Scientific Approach A2i Therapeutics is developing small molecule inhibitors […]

  • Bsense Bio Therapeutics

    Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

  • Circuit-Bio

    Circuit-Bio is a synthetic biology company developing an innovative unique platform of logical gene circuits for cancer immunotherapy. The Company’s platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. Thus, the circuit selectively converts cancer cells into ‘Trojan horses’ utilize […]

  • Epeius Pharma

    Epeius pharma is a cell and gene therapy company developing next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). Efficient and predictable therapeutics delivery is particularly challenging in neurological diseases due to the blood-brain barrier (BBB), which tightly regulates the transport of molecules to the brain, and blocks the […]

  • GliXogen Therapeutics

    GliXogen Therapeutics is developing a treatment to enhance remyelination in neurodegenerative disorders which are driven by damage to the neuron’s myelin sheath, such as multiple sclerosis (MS).

  • JAMM Therapeutics

    JAMM Therapeutics is a drug discovery company developing small molecule modulators of the BRISC deubiquitinating (DUB) enzyme complex, an important regulator of type I interferon (IFN) signaling, for the treatment of systemic lupus erythematosus (SLE). Scientific background Type I IFNs are a family of cytokines that are characterized by their antiviral, antiproliferative, and immunomodulatory activities. […]

  • MOYA Bio

    MOYA Bio is developing a novel class of tumor immune conditioning agents. The company’s first-in-class inhibitors of the FAT10 pathway are envisioned to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations.

  • Nevrox

    Nevrox, is a drug discovery company developing a neuroprotective small molecule modulator of protein disulfide isomerase (PDI) for the treatment of Huntington disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

  • PINK Biopharma

    PiNK Biopharma is developing a novel immuno-oncology approach based on a novel NK checkpoint.

  • Ramino-Bio

    Ramino-Bio is developing treatments for cardiometabolic diseases by enhancing branched-chain amino acids (BCAAs; Valine, leucine, and Isoleucine) catabolism. Diet, obesity, genetics, and gut microbiota can increase circulating BCAAs above the normal level.  Chronically elevated levels of circulating BCAAs are known to be a propagating factor for cardiac hypertrophy, muscle lipid accumulation, hepatic lipid storage, and […]

  • Selene Therapeutics

    Selene Therapeutics is pioneering a new therapeutic strategy for treating refractory epilepsy – regulation of the neuronal activity set point by reduction of the  neuronal mean firing rate (MFR). Selene aims to develop small molecule for inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrial membrane and participating in several key […]

  • Skip Therapeutics

    Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases by applying a novel, proprietary, computational engine to directly identify patient cohorts and determine therapeutic designs. SCIENTIFIC BACKGROUND Thousands of rare genetic disorders affect millions of people worldwide, however the small number of patients for each disease, further segregated by patient-specific mutations, has hindered development […]

  • TNIK Therapeutics

    TNIK Therapeutics target cancer stem cell diseases by developing small molecule inhibitors of TNIK, the most downstream transcription regulator of the Wnt pathway that is a major force driving colorectal carcinogenesis when over activated.

Incubator Graduates

  • BiomX

    Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.

  • ImmPACT-Bio

    ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.

  • Pi Therapeutics

    Pi Therapeutics is a preclinical-stage pharmaceutical company a first-in-class small molecule cancer drug

  • Protekt Therapeutics

    Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)

Font Resize